This study shows that a 12-week moderate-intensity AT may not change IL-1β, TNF-α, IFN-γ, IL-10, IRS-2, and MMP-9 mRNA expression levels in PBMC of MS women. This evidence concerns the gene IL1B and myeloid sarcoma.